Further research demonstrates that targeting NAT10 with Remodelin exhibits anticancer activity in gastric cancer and enhances the antitumor efficacy of Mdm2 inhibitors in p53 wild-type gastric cancer (Deng et al., 2023). This evidence concerns the gene NAT10 and gastric cancer.